Nina Tunariu
Overview
Explore the profile of Nina Tunariu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
7511
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel P, Dreibe S, Attard G, Cole A, Diez P, Frew J, et al.
Int J Radiat Oncol Biol Phys
. 2025 Mar;
PMID: 40068778
Purpose: Optimal management of oligoprogressive prostate cancer whilst on androgen receptor pathway inhibitors (ARPi) is not known. The **** trial tests the role of stereotactic body radiotherapy (SBRT) in this...
2.
Castagnoli F, Dragan A, Candito A, Tunariu N, Messiou C, Koh D
Magn Reson Imaging
. 2025 Jan;
117:110331.
PMID: 39855367
Introduction: Whole-body MRI (WB-MRI) is increasingly used in clinical practice for detection of malignant bone disease. A high relative contrast ratio (RCR) of malignant bone lesions compared with normal bone...
3.
Welti J, Bogdan D, Figueiredo I, Coleman I, Jimenez Vacas J, Liodaki K, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39787247
Purpose: Advanced prostate cancer (PCa) is invariably fatal with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men with advanced PCa,...
4.
Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, et al.
Cancer Cell
. 2024 Nov;
42(12):2113-2123.e4.
PMID: 39577422
PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects. However, mechanisms underlying PARPi resistance are not fully understood. While acquired mutations restoring...
5.
Rata M, Orton M, Tunariu N, Curcean A, Hughes J, Scurr E, et al.
Eur Radiol
. 2024 Nov;
PMID: 39505736
Objectives: MR fingerprinting (MRF) has the potential to quantify treatment response. This study evaluated the repeatability of MRF-derived T and T relaxation times in bone metastasis, bone, and muscle in...
6.
Westaby D, Jimenez-Vacas J, Figueiredo I, Rekowski J, Pettinger C, Gurel B, et al.
J Clin Invest
. 2024 Sep;
134(18).
PMID: 39286979
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage...
7.
Cattabriga A, Renzetti B, Galuppi F, Bartalena L, Gaudiano C, Brocchi S, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061171
Prostate cancer ranks among the most prevalent tumours globally. While early detection reduces the likelihood of metastasis, managing advanced cases poses challenges in diagnosis and treatment. Current international guidelines support...
8.
Padhani A, Tunariu N, Perez-Lopez R, Tombal B, Lecouvet F
Eur Radiol
. 2024 Jun;
34(12):7564-7566.
PMID: 38902565
No abstract available.
9.
Donners R, Candito A, Rata M, Sharp A, Messiou C, Koh D, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730599
(1) Background: We assessed the test-re-test repeatability of radiomics in metastatic castration-resistant prostate cancer (mCPRC) bone disease on whole-body diffusion-weighted (DWI) and T1-weighted Dixon MRI. (2) Methods: In 10 mCRPC...
10.
James N, Tannock I, Ndow J, Feng F, Gillessen S, Ali S, et al.
Lancet
. 2024 Apr;
403(10437):1683-1722.
PMID: 38583453
No abstract available.